Literature DB >> 34295566

PADI1 contributes to EMT in PAAD by activating the ERK1/2-p38 signaling pathway.

Tengfei Ji1, Keqiang Ma1, Liang Chen1, Tiansheng Cao1.   

Abstract

BACKGROUND: Peptidylarginine deiminase 1 (PADI1) has been reported to promote tumorigenesis in breast cancer. However, the functional role of PADI1 in pancreatic ductal adenocarcinoma (PAAD) has remained elusive until now.
METHODS: The expression pattern of PADI1 in PAAD tissues and normal tissues was analyzed using The Cancer Genome Atlas (TCGA) dataset. A Kaplan-Meier curve analysis was performed to evaluate the prognostic value of PADI1 in PAAD patients. PADI1 was knocked down in CFPAN-1 and HPAC cells, and overexpressed in PANC-1 and Bxpc-3 cells by RNA interference. A wound-healing assay was performed to analyze relative cell migration distance. Cell migration and invasion were assessed by a Transwell assay. Related protein expression levels were measured by western blot and immunofluorescence.
RESULTS: The bioinformatics analysis showed that PADI1 was overexpressed in PAAD tissues and associated with a poor survival prognosis. The knockdown of PADI1 suppressed cell migration and invasion, and activated the ERK1/2-p38 signaling pathway in CFPAN-1 and HPAC cells. The overexpression of PADI1 produced the opposite results in PANC-1 and Bxpc-3 cells. Additionally, treatment with an MEK1/2 inhibitor significantly attenuated the effects of PADI1 knockdown on cell migration, invasion, the epithelial-mesenchymal transition (EMT) process, and p-ERK1/2 and p38 expression in CFPAN-1 and HPAC cells.
CONCLUSIONS: Our data suggested that PADI1 may function as an oncogene in regulating metastasis in vitro in PAAD. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  ERK1/2-p38 signaling; Pancreatic ductal adenocarcinoma (PAAD); epithelial-mesenchymal transition process (EMT process); peptidylarginine deiminase 1 (PADI1)

Year:  2021        PMID: 34295566      PMCID: PMC8261327          DOI: 10.21037/jgo-21-283

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  29 in total

1.  Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway.

Authors:  Jin-Hao Miao; Shu-Qiang Wang; Ming-Hui Zhang; Feng-Bin Yu; Lei Zhang; Zhong-Xiang Yu; Yong Kuang
Journal:  Oncol Rep       Date:  2014-07-24       Impact factor: 3.906

2.  Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis.

Authors:  Zhenzhen Li; Xianghua Liu; Baoying Wang; Yali Nie; Jianguo Wen; Qingwei Wang; Chaohui Gu
Journal:  Nephrology (Carlton)       Date:  2017-08       Impact factor: 2.506

3.  PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.

Authors:  Hao Qin; Xiaoqiu Liu; Fujun Li; Lixia Miao; Tingting Li; Boqun Xu; Xiaofei An; Aaron Muth; Paul R Thompson; Scott A Coonrod; Xuesen Zhang
Journal:  Cancer Lett       Date:  2017-08-24       Impact factor: 8.679

4.  Overexpression of PAD4 suppresses drug resistance of NSCLC cell lines to gefitinib through inhibiting Elk1-mediated epithelial-mesenchymal transition.

Authors:  Qiong Duan; Cui Pang; Ning Chang; Ju Zhang; Wenchao Liu
Journal:  Oncol Rep       Date:  2016-04-28       Impact factor: 3.906

5.  Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway.

Authors:  Jie Zhu; Ya Zheng; Haiyan Zhang; Yanmei Liu; Hong Sun; Pengnan Zhang
Journal:  Am J Transl Res       Date:  2019-06-15       Impact factor: 4.060

Review 6.  MAP kinase signalling pathways in cancer.

Authors:  A S Dhillon; S Hagan; O Rath; W Kolch
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 7.  PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease.

Authors:  Erik R Vossenaar; Albert J W Zendman; Walther J van Venrooij; Ger J M Pruijn
Journal:  Bioessays       Date:  2003-11       Impact factor: 4.345

8.  PADI4 modulates the invasion and migration of osteosarcoma cells by down-regulation of epithelial-mesenchymal transition.

Authors:  Qiaoli Zhai; Jie Qin; Xiaodong Jin; Xiaoyu Sun; Linping Wang; Wenyan Du; Tao Li; Xinxin Xiang
Journal:  Life Sci       Date:  2020-06-13       Impact factor: 5.037

Review 9.  The role of PARP inhibitors in BRCA mutated pancreatic cancer.

Authors:  Jeffrey Chi; Su Yun Chung; Ruwan Parakrama; Fatima Fayyaz; Jyothi Jose; Muhammad Wasif Saif
Journal:  Therap Adv Gastroenterol       Date:  2021-05-10       Impact factor: 4.409

10.  Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis.

Authors:  Sebastian R Nielsen; Valeria Quaranta; Andrea Linford; Perpetua Emeagi; Carolyn Rainer; Almudena Santos; Lucy Ireland; Takao Sakai; Keiko Sakai; Yong-Sam Kim; Dannielle Engle; Fiona Campbell; Daniel Palmer; Jeong Heon Ko; David A Tuveson; Emilio Hirsch; Ainhoa Mielgo; Michael C Schmid
Journal:  Nat Cell Biol       Date:  2016-04-18       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.